{"id":451200,"date":"2021-03-04T16:04:15","date_gmt":"2021-03-04T21:04:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451200"},"modified":"2021-03-04T16:04:15","modified_gmt":"2021-03-04T21:04:15","slug":"nucana-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-business-update\/","title":{"rendered":"NuCana Reports Fourth Quarter and Year-End 2020 Financial Results\u00a0and Provides Business Update"},"content":{"rendered":"
\n

\n
\n Presented Encouraging Clinical Data for NUC-3373 and NUC-7738<\/em>
\n <\/strong>
\n \n <\/p>\n

\n
\n Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval Filing <\/em>
\n <\/strong>\n <\/p>\n

\n
\n Raised $80 million in a Follow-on Offering <\/em>
\n <\/strong>\n <\/p>\n

\n
\n Augmented the Board of Directors with Two Key Appointments<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Numerous Clinical Data Announcements and Study Initiations Expected in 2021<\/em>
\n <\/strong>\n <\/p>\n

EDINBURGH, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.<\/p>\n

As of December 31, 2020, NuCana had cash and cash equivalents of \u00a387.4 million compared to \u00a3100.7 million at September 30, 2020 and \u00a352.0 million at December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of \u00a312.3 million for the quarter ended December 31, 2020, as compared to \u00a37.7 million for the quarter ended December 31, 2019. Net loss for the year ended December 31, 2020 was \u00a330.7 million, compared to a net loss of \u00a321.4 million for the year ended December 31, 2019. Basic and diluted loss per share was \u00a30.24 for the quarter and \u00a30.81 for the year ended December 31, 2020, as compared to \u00a30.24 per share for the comparable quarter and \u00a30.66 for the year ended December 31, 2019.<\/p>\n

\u201c2020 was a very successful year for NuCana,\u201d said Hugh S. Griffith, NuCana\u2019s Founder and Chief Executive Officer. \u201cAgainst the challenging backdrop of the COVID-19 pandemic, we continued to advance all of our clinical programs and generate encouraging clinical and non-clinical data. Throughout 2020, we made good progress in the Phase III NuTide:121 biliary tract cancer study and expect to enroll sufficient patients in 2021 to complete the first interim analysis in 2022, which may support an accelerated approval filing. In September, we provided an update on two of our lead programs at ESMO that further validate the use of our proprietary ProTide technology. NUC-3373 continued to demonstrate its potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU in patients with colorectal cancer. We also announced the first-ever clinical data for NUC-7738, which showed promising indications of anti-cancer activity and a favorable tolerability profile.\u201d<\/p>\n

Mr. Griffith continued: \u201cDuring 2020, we completed a successful $80 million follow-on offering that significantly strengthens our balance sheet. We also appointed a new non-executive Chairman, Andrew Kay and a new non-executive director, Bali Muralidhar. Both individuals bring a wealth of experience and we look forward to their contributions as we advance NuCana\u2019s programs.\u201d<\/p>\n

Mr. Griffith concluded: \u201cWe were excited to begin 2021 with the announcement of additional interim data for NUC-3373 in patients with colorectal cancer that continued to demonstrate encouraging efficacy and safety at ASCO GI. We look forward to continuing to drive recruitment across all of our ongoing studies, announce additional clinical data, and initiate new studies in 2021. We remain focused on our mission of significantly improving treatment outcomes for patients with cancer.\u201d<\/p>\n

\n Anticipated 2021 Milestones <\/strong>\n <\/p>\n